

Karen Quillen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4427436/publications.pdf>

Version: 2024-02-01

91
papers

2,628
citations

304743

22
h-index

189892

50
g-index

92
all docs

92
docs citations

92
times ranked

2379
citing authors

#	ARTICLE	IF	CITATIONS
1	High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study. <i>Annals of Internal Medicine</i> , 2004, 140, 85.	3.9	539
2	Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. <i>Blood</i> , 2011, 118, 4346-4352.	1.4	259
3	Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. <i>Blood</i> , 2001, 97, 1885-1887.	1.4	200
4	Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. <i>Trials</i> , 2013, 14, 73.	1.6	198
5	Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. <i>Blood</i> , 2007, 110, 3561-3563.	1.4	154
6	Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. <i>Blood</i> , 2004, 104, 1888-1893.	1.4	109
7	Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. <i>Blood</i> , 2015, 126, 2345-2347.	1.4	109
8	SARS-CoV-2 Infection-associated Hemophagocytic Lymphohistiocytosis. <i>American Journal of Clinical Pathology</i> , 2020, 154, 466-474.	0.7	103
9	Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. <i>Haematologica</i> , 2009, 94, 1661-1668.	3.5	84
10	Probiotic-associated high-titer anti-B in a group A platelet donor as a cause of severe hemolytic transfusion reactions. <i>Transfusion</i> , 2009, 49, 1845-1849.	1.6	71
11	A practical strategy to reduce the risk of passive hemolysis by screening plateletpheresis donors for high-titer ABO antibodies. <i>Transfusion</i> , 2011, 51, 92-96.	1.6	58
12	Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1445-1451.	2.0	55
13	High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. <i>Blood</i> , 2012, 120, 4445-4446.	1.4	38
14	Quality Improvement to Decrease Specimen Mislabeling in Transfusion Medicine. <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 1196-1198.	2.5	35
15	Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. <i>Haematologica</i> , 2011, 96, 1890-1892.	3.5	34
16	Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. <i>Blood</i> , 2006, 108, 3945-3947.	1.4	33
17	Prevalence of RhD Variants, Confirmed by Molecular Genotyping, in a Multiethnic Prenatal Population. <i>American Journal of Clinical Pathology</i> , 2010, 134, 438-442.	0.7	32
18	High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 127-132.	2.0	31

#	ARTICLE	IF	CITATIONS
19	Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation. <i>Blood</i> , 2017, 130, 1383-1386.	1.4	30
20	Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte colony-stimulating factor and dexamethasone. <i>Transfusion</i> , 2009, 49, 513-518.	1.6	26
21	Hypotensive Transfusion Reactions in Patients Taking Angiotensin-Converting Enzyme Inhibitors. <i>New England Journal of Medicine</i> , 2000, 343, 1422-1423.	27.0	25
22	Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease. <i>Haematologica</i> , 2009, 94, 1029-1032.	3.5	25
23	PREVALENCE OF CEFTRIAXONE-INDUCED RED BLOOD CELL ANTIBODIES IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE AND HUMAN IMMUNODEFICIENCY VIRUS INFECTION. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, 357-358.	2.0	23
24	The determinants of granulocyte yield in 1198 granulocyte concentrates collected from unrelated volunteer donors mobilized with dexamethasone and granulocyte colony-stimulating factor: a 13-year experience. <i>Transfusion</i> , 2009, 49, 421-426.	1.6	20
25	Thrombotic Microangiopathy: A Multidisciplinary Team Approach. <i>American Journal of Kidney Diseases</i> , 2017, 70, 715-721.	1.9	20
26	A Novel Sickle Hemoglobin: Hemoglobin S-South End. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 773-776.	0.6	18
27	Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: A case report with literature review. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2009, 16, 103-107.	3.0	16
28	Screening plateletpheresis donors for HLA antibodies on two high-throughput platforms and correlation with recipient outcome. <i>Transfusion</i> , 2011, 51, 504-510.	1.6	16
29	Hemolysis from platelet transfusion: call to action for an underreported reaction. <i>Transfusion</i> , 2012, 52, 2072-2074.	1.6	15
30	Pericardial effusion: A rare presentation of adult T-cell leukemia/lymphoma. <i>American Journal of Hematology</i> , 2004, 77, 381-383.	4.1	14
31	Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis. <i>Annals of Hematology</i> , 2010, 89, 579-584.	1.8	14
32	A Massive Transfusion Protocol Incorporating a Higher FFP/RBC Ratio Is Associated With Decreased Use of Recombinant Activated Factor VII in Trauma Patients. <i>American Journal of Clinical Pathology</i> , 2012, 137, 566-571.	0.7	14
33	Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e169-e173.	2.0	14
34	Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 88.	6.2	14
35	Amyloid Deposits in the Bone Marrow of Patients with Immunoglobulin Light Chain Amyloidosis Do Not Impact Stem Cell Mobilization or Engraftment. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1935-1938.	2.0	13
36	Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19 via Multi-Parameter Detection. <i>Frontiers in Immunology</i> , 2021, 12, 614676.	4.8	13

#	ARTICLE	IF	CITATIONS
37	Blood and bombs: blood use after the Boston Marathon bombing of April 15, 2013. <i>Transfusion</i> , 2014, 54, 1202-1203.	1.6	12
38	Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1823-1827.	2.0	12
39	Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 149-153.	3.0	11
40	Acquired Glanzmann Thrombasthenia Associated With Hodgkin Lymphoma: Rapid Reversal of Functional Platelet Defect With ABVD (Adriamycin/Bleomycin/Vinblastine/Dacarbazine) Chemotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e51-e54.	0.4	10
41	Relapse Rate and Long-Term Survival of AL Amyloidosis Patients Treated with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT). <i>Blood</i> , 2006, 108, 3094-3094.	1.4	10
42	Low-dose recombinant activated factor VII in massively transfused trauma patients with coagulopathy. <i>Transfusion</i> , 2007, 47, 749-751.	1.6	8
43	Successful Long-Term Management of Aneurysm-Associated Chronic Disseminated Intravascular Coagulation with Low Molecular Weight Heparin. <i>Journal of Cardiac Surgery</i> , 2012, 27, 730-735.	0.7	7
44	Successful Treatment of AL Amyloidosis Patients over Age 65 with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT). <i>Blood</i> , 2004, 104, 923-923.	1.4	7
45	Vascular erosion caused by a double-lumen central venous catheter during therapeutic plasma exchange. <i>Transfusion</i> , 1995, 35, 510-512.	1.6	6
46	Acute Oxaliplatin-induced Hemolytic Anemia, Thrombocytopenia, and Renal Failure: Case Report and a Literature Review. <i>Clinical Colorectal Cancer</i> , 2017, 16, e105-e107.	2.3	5
47	Hemovigilance in Massachusetts and the adoption of statewide hospital blood bank reporting using the National Healthcare Safety Network. <i>Transfusion</i> , 2017, 57, 478-483.	1.6	5
48	Effect of Hydroxyurea on Immature Reticulocyte Fraction in Sickle Cell Anemia. <i>Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology</i> , 2007, 13, 93-97.	1.2	5
49	Heparin-induced thrombocytopenia and thrombosis during high dose melphalan and autologous stem cell transplantation. <i>Blood</i> , 2018, 132, 755-757.	1.4	4
50	High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators. <i>Bone Marrow Transplantation</i> , 2019, 54, 1304-1309.	2.4	4
51	Feasibility of Second Autologous Peripheral Blood Stem Cell (PBSC) Collection Followed by a Second Cycle of High Dose Melphalan (HDM) in Patients Relapsing after an Initial Course of HDM for the Treatment of AL Amyloidosis. <i>Blood</i> , 2004, 104, 5226-5226.	1.4	4
52	Treatment of AL Amyloidosis with Two Cycles of Induction Therapy with Bortezomib and Dexamethasone Followed by Bortezomib-High Dose Melphalan Conditioning and Autologous Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 2019-2019.	1.4	4
53	Concurrent Presentation of Thrombotic Thrombocytopenic Purpura and Membranous Nephropathy. <i>Kidney International Reports</i> , 2018, 3, 476-481.	0.8	3
54	Genes Associated with Alloimmunization to Blood Group Antigens in Sickle Cell Disease. <i>Blood</i> , 2014, 124, 762-762.	1.4	3

#	ARTICLE	IF	CITATIONS
55	In search of plentiful universal donor plasma: what might <sc>L</sc>andsteiner say?. Transfusion, 2013, 53, 1863-1864.	1.6	2
56	Nonoperative Management of Spontaneous Splenic Rupture in a Patient with Light-Chain Amyloidosis: A Case Report. Journal of Vascular and Interventional Radiology, 2015, 26, 1578-1580.	0.5	2
57	High-dose melphalan and stem cell transplantation in AL amyloidosis with elevated cardiac biomarkers. Bone Marrow Transplantation, 2018, 53, 1593-1595.	2.4	2
58	Distinctive pseudopalised histiocytic hyperplasia characterizes the transition of exudative to proliferative phase of diffuse alveolar damage in patients dying of COVID-19. Human Pathology, 2021, 116, 49-62.	2.0	2
59	A Genome-Wide Association Study of the Alloimmunization Responder Phenotype in Sickle Cell Disease.. Blood, 2009, 114, 2551-2551.	1.4	2
60	Transfusion of Red Cells. New England Journal of Medicine, 2016, 374, e12.	27.0	1
61	Evaluation of a new continuous mononuclear cell collection procedure in a single transplant center cohort enriched for AL amyloidosis patients. Transfusion and Apheresis Science, 2018, 57, 411-415.	1.0	1
62	Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study. Blood, 2019, 134, 4578-4578.	1.4	1
63	Bortezomib and High Dose Melphalan Followed by Autologous Stem Cell Transplantation (BortHDM/SCT) for the Treatment of AL Amyloidosis: Results of a Feasibility Study.. Blood, 2009, 114, 4353-4353.	1.4	1
64	High-Dose Melphalan and Autologous Stem Cell Transplantation In AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease Associated End-Stage Renal Disease Requiring Dialysis. Blood, 2010, 116, 3553-3553.	1.4	1
65	Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center. Blood, 2013, 122, 3328-3328.	1.4	1
66	The Incidence of Atrial Fibrillation Among Patients with AL Amyloidosis Undergoing High Dose Melphalan and Stem Cell Transplantation (HDM/SCT): Experience at a Single Institution. Blood, 2015, 126, 5490-5490.	1.4	1
67	Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients. Blood, 2010, 116, 2394-2394.	1.4	1
68	The trials and tribulations of chronic transfusion in pediatric sickle cell disease: progress from STOP to TWITCH?. Transfusion, 2016, 56, 1673-1674.	1.6	0
69	Recurrent focal segmental glomerulosclerosis apparently resistant to plasmapheresis improves after surgical repair of arteriovenous fistula aneurysms. CKJ: Clinical Kidney Journal, 2016, 9, 408-410.	2.9	0
70	Teach, listen, love: a personalised approach to supervising doctors in training. Postgraduate Medical Journal, 2018, 94, 730-730.	1.8	0
71	Quality Management of massive transfusion protocol incorporating tranexamic acid adherence. Transfusion and Apheresis Science, 2018, 57, 785-789.	1.0	0
72	Monoclonal IgG4/2 ^Î Deposition Following Eculizumab Therapy for Recurrent Atypical Hemolytic Uremic Syndrome in Kidney Transplantation. Kidney Medicine, 2019, 1, 139-143.	2.0	0

#	ARTICLE	IF	CITATIONS
73	Peripheral blood smear and hemoglobin electrophoresis of unsuspected hemoglobin Bart's hydrops fetalis in a newborn. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 53-54.	1.3	0
74	High-Dose Melphalan and Autologous Stem Cell Transplantation in Unusual Non-Amyloid Light Chain Deposition Disorders.. <i>Blood</i> , 2005, 106, 5476-5476.	1.4	0
75	Efficacy of Low-Dose Recombinant Activated Factor VII (rFVIIa) in Massively Transfused Trauma Patients with Coagulopathy.. <i>Blood</i> , 2005, 106, 950-950.	1.4	0
76	Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis Predict Treatment Outcomes.. <i>Blood</i> , 2005, 106, 1160-1160.	1.4	0
77	Treatment of AL Amyloidosis with Tandem Cycles of High Dose Melphalan and Autologous Stem Cell Transplantation: Final Analysis of a Prospective Trial.. <i>Blood</i> , 2006, 108, 612-612.	1.4	0
78	Second Autologous Peripheral Blood Stem Cell Transplantation with High Dose Melphalan (HDM/SCT) in Patients Relapsing After An Initial Course of HDM/SCT for the Treatment of AL Amyloidosis.. <i>Blood</i> , 2009, 114, 2318-2318.	1.4	0
79	Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis.. <i>Blood</i> , 2009, 114, 4352-4352.	1.4	0
80	Long Term Results of High-Dose Melphalan and Autologous Stem Cell Transplantation in Non-Amyloid Monoclonal Immunoglobulin Deposition Disorders.. <i>Blood</i> , 2009, 114, 4356-4356.	1.4	0
81	High-Dose Melphalan and Stem Cell Transplantation for Patients with AL Amyloidosis and Cardiac Involvement. <i>Blood</i> , 2011, 118, 2043-2043.	1.4	0
82	Acquired Glanzmann's Thrombasthenia Associated with Hodgkin Lymphoma: Rapid Reversal of Functional Platelet Defect with Chemotherapy Despite Persistence of a Glycoprotein lib/IIIA Auto-Antibody. <i>Blood</i> , 2012, 120, 4656-4656.	1.4	0
83	Diagnosis and Management of Platelet Alloimmunization. , 2013, 10, .		0
84	Proteasome Inhibitor Based Protocol For Antibody Mediated Rejection In Kidney Transplantation. <i>Blood</i> , 2013, 122, 4728-4728.	1.4	0
85	Effect of Severe Hypoalbuminemia on Myelosuppression and Other Toxicities of High Dose Melphalan and Autologous Stem Cell Transplantation in AL Amyloidosis Patients. <i>Blood</i> , 2014, 124, 5906-5906.	1.4	0
86	Effect of Severe Hypoalbuminemia on Myelosuppression and Other Toxicities of High Dose Melphalan and Autologous Stem Cell Transplantation in AL Amyloidosis Patients. <i>Blood</i> , 2015, 126, 5499-5499.	1.4	0
87	A Retrospective Review of Engraftment Data for Tbo-Filgrastim Vs. Filgrastim in Patients Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 5484-5484.	1.4	0
88	Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed By Autologous Stem Cell Transplantation for AL Amyloidosis: Long Term Follow-up Analysis. <i>Blood</i> , 2018, 132, 4616-4616.	1.4	0
89	Safety of Autologous Stem Cell Transplantation in Patients with Known HTLV-1 Infection: A Case Series of 4 Patients. <i>Blood</i> , 2018, 132, 5738-5738.	1.4	0
90	Early Serum Free Light Chain Response after High-Dose Melphalan and Stem Cell Transplantation Predicts Hematologic Response in AL Amyloidosis. <i>Blood</i> , 2020, 136, 26-26.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Modified High Dose Versus High Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2020, 136, 4-5.	1.4	0